Madrigal Pharmaceuticals (MDGL) Operating Leases (2019 - 2026)

Madrigal Pharmaceuticals (MDGL) has 8 years of Operating Leases data on file, last reported at $5.3 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $5.3 million, up 604.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (up 604.53% YoY), and the FY2025 annual result was $6.7 million, up 561.2% from the prior year.
• Operating Leases retreated to $5.3 million in Q1 2026 per MDGL's latest filing, from $6.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $6.7 million in Q4 2025 and troughed at $71000.0 in Q3 2022.
• A 5-year average of $2.1 million and a median of $1.1 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases plunged 85.54% in 2022, then soared 1763.38% in 2023.
• A 5-year view of Operating Leases shows it stood at $71000.0 in 2022, then surged by 1570.42% to $1.2 million in 2023, then dropped by 14.17% to $1.0 million in 2024, then jumped by 561.2% to $6.7 million in 2025, then retreated by 21.5% to $5.3 million in 2026.
• Business Quant data shows MDGL's Operating Leases at $5.3 million in Q1 2026, $6.7 million in Q4 2025, and $5.6 million in Q3 2025.